Amit Bar-Or

In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.

Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.

Classified as: Research, The Neuro, Amit Bar-Or, MS, health and lifestyle, Douglas Arnold, ocrelizumab
Category:
Published on: 9 Jan 2017

Drug shown to reduce new attacks/symptom progression in some patients

In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.

Classified as: Multiple Sclerosis, Amit Bar-Or, MS, Douglas Arnold, ocrelizumab
Published on: 22 Dec 2016

A new study led by researchers at the Montreal Neurological Institute and Hospital of McGill University and the MUHC, gets closer to identifying the mechanisms responsible for multiple sclerosis and makes headway in the search for better treatments.

Classified as: Montreal Neurological Institute, Multiple Sclerosis, Amit Bar-Or, MS, B cell depletion therapy, B cell depletion, B cell
Category:
Published on: 23 Oct 2015

Powerful treatment improves patients’ lives and provides new insight into mechanisms of the disease

Classified as: neuroscience, brain, treatment, neurological, Multiple Sclerosis, Amit Bar-Or, bone marrow, MS, stem cells, transplant
Category:
Published on: 26 Mar 2013